{"filing":{"accession_number":"0001213900-26-098414","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304823-6k_neurosense.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026098414/ea0304823-6k_neurosense.htm"},"events":[{"id":32388,"run_id":29754,"accession_number":"0001213900-26-098414","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"summary":"The filing announces a 1-for-20 reverse share split, consolidating 37,938,036 shares into 1,896,902 shares effective September 14, 2026. While reverse splits are typically governance/administrative actions, this one is material to investors as it signals potential delisting risk or financial distress (reverse splits are often undertaken to maintain minimum share price requirements for exchange listing). However, the event does not cleanly fit the taxonomy: it is not a dilutive issuance (which involves new equity), nor is it clearly delisting_risk (no explicit delisting notice), nor governance_other (no board/leadership change). The reverse split itself is a capital restructuring with material implications for share value and listing status, but the taxonomy lacks a precise category for this type of corporate action.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":35551,"accession_number":"0001213900-26-098414","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The filing announces a 1-for-20 reverse share split, consolidating 37,938,036 shares into 1,896,902 shares effective September 14, 2026. While reverse splits are typically governance/administrative actions, this one is material to investors as it signals potential delisting risk or financial distress (reverse splits are often undertaken to maintain minimum share price requirements for exchange listing). However, the event does not cleanly fit the taxonomy: it is not a dilutive issuance (which involves new equity), nor is it clearly delisting_risk (no explicit delisting notice), nor governance_other (no board/leadership change). The reverse split itself is a capital restructuring with material implications for share value and listing status, but the taxonomy lacks a precise category for this type of corporate action.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:32:22.239380+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-09-09"}]}